Cloud Banner

Pharmaceutical

Image

Global Neuroendocrine Tumors Market – Industry Trends and Forecast to 2031

  • Pharmaceutical
  • Upcoming Report
  • Feb 2024
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Neuroendocrine Tumors Market, By Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), and Appendicular), Grade (Grade 1, Grade 2, and Grade 3), Type (Diagnosis and Treatment), Product (Somatostatin Analogs,Targeted Therapy, and Chemotherapy), Route of Administration (Oral and Parenteral),  End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), Distribution Channel  (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other)– Industry Trends and Forecast to 2031.

Neuroendocrine Tumors Market

Neuroendocrine Tumors Market Analysis and Size

In the neuroendocrine tumors market, treatments cater to tumors originating from organs such as the lung, pancreas, and gastrointestinal tract. For instance, lung neuroendocrine tumors, including small cell lung cancer, necessitate specialized therapies such as chemotherapy and immunotherapy. Pancreatic NETs may require surgery, peptide receptor radionuclide therapy, or targeted drug treatments. Gastrointestinal NETs often involve somatostatin analogs, targeted therapies, or surgical interventions tailored to tumor size and spread.

Data Bridge Market Research analyses that the global neuroendocrine tumors market, which was USD 3,232.02 million in 2023, is expected to reach 7,132.24 million by 2031, at a CAGR of 10.4% during the forecast period 2024 to 2031. In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Neuroendocrine Tumors Market Scope and Segmentation  

Report Metric

Details

Forecast Period

2024 to 2031

Base Year

2023

Historic Years

2022 (Customizable to 2016-2021)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Classification (Functional Net and Non-Functional Net), Site (Lung, Pancreas, Gastrointestinal Tract (GI), and Appendicular), Grade (Grade 1, Grade 2, and Grade 3), Type (Diagnosis and Treatment), Product (Somatostatin Analogs,Targeted Therapy, and Chemotherapy), Route of Administration (Oral and Parenteral),  End User (Hospitals, Specialty Clinics, Radiation Centers, Home Healthcare, and Others), Distribution Channel  (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb (U.S.), Viatris Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Novartis AG (Switzerland), Regeneron Pharmaceuticals, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Lupin (India), Exact Sciences Corporation (U.S.), Pfizer Inc. (U.S.), Ipsen Pharma (France), Advanced Accelerator Applications (France), BioSynthema Inc. (U.S.), Bionano Genomics, Inc.U.S.), Illumina, Inc. (U.S.), GSK plc (U.K.), HUTCHMED (China)

Market Opportunities

  • Growing Demand for Personalized to Meet Individual Needs
  • Advanced Imaging Techniques Enhancing Early Diagnosis

Market Definition

Neuroendocrine tumors (NETs) are neoplasms arising from neuroendocrine cells found throughout the body, particularly in organs such as the gastrointestinal tract, pancreas, and lungs. These tumors exhibit heterogeneous clinical behaviors and can secrete various hormones or bioactive substances, contributing to diverse symptomatology and diagnostic complexities. Treatment modalities depend on tumor characteristics and staging.

Global Neuroendocrine Tumors Market Dynamics

Drivers

  • Growing Awareness among Healthcare Professionals

Healthcare professionals are witnessing a rise in awareness regarding neuroendocrine tumors. This surge is fueled by ongoing research and educational efforts. With enhanced understanding, professionals can provide more precise diagnoses and tailor treatment plans accordingly. Such advancements are pivotal in improving patient outcomes and ensuring better management of neuroendocrine tumors, ultimately contributing to enhanced patient care and well-being.

  • Rising Incidence of Neuroendocrine Tumors Globally

The neuroendocrine tumors market is witnessing a notable increase in global incidence rates. This rise is attributed to improved diagnostic techniques, leading to better detection and reporting. Additionally, lifestyle factors and environmental influences contribute to the growing prevalence. As awareness among healthcare professionals and the general population increases, there's a heightened focus on early detection and treatment strategies, underscoring the importance of addressing this rising health concern effectively.

Opportunities

  • Growing Demand for Personalized to Meet Individual Needs

In the neuroendocrine tumors market, there is increasing demand for personalized medicine strategies that cater to individual patient requirements. This trend presents a significant opportunity for innovative therapies and targeted treatment approaches. By tailoring interventions to specific patient characteristics and tumor profiles, healthcare providers can optimize treatment outcomes and improve patient satisfaction, underscoring the potential for advancements in neuroendocrine tumor management.

  • Advanced Imaging Techniques Enhancing Early Diagnosis

The neuroendocrine tumors market benefits from the rising adoption of advanced imaging techniques, such as positron emission tomography (PET) scans and functional MRI. These technologies enable early detection and precise monitoring of tumor progression, facilitating timely interventions and personalized treatment plans. Improved diagnostic accuracy and treatment monitoring contribute to better patient outcomes, driving the market's growth and enhancing healthcare delivery for neuroendocrine tumor patients.

Restraints/Challenges

  • High Costs Limits Accessibility for Patients and Healthcare Facilities

The high costs of advanced imaging techniques and treatment modalities restrain market growth by limiting accessibility for patients and healthcare facilities. This constraint impedes timely diagnosis and optimal management, particularly in regions with limited resources. Additionally, it poses financial burdens on healthcare systems and patients, potentially delaying treatment initiation and hindering overall market expansion for neuroendocrine tumor therapies and diagnostics.

  • Lack of Standardization Leads to Delayed, Inaccurate Diagnoses

The lack of standardized diagnostic criteria for neuroendocrine tumors poses a challenge by leading to variability in diagnosis and treatment decisions. This inconsistency can result in delayed or inaccurate diagnoses, affecting patient outcomes and hindering market growth. Without clear guidelines, clinicians may struggle to effectively manage patients, impacting the adoption of treatments and diagnostics and potentially limiting the overall market expansion for neuroendocrine tumor therapies.

This global neuroendocrine tumors market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global neuroendocrine tumors market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

  • In April 2023, researchers from Cambridge University partnered with the Spanish National Cancer Research Center (CNIO) in Madrid to globally collaborate on genomic studies of rare neuroendocrine tumors, namely pheochromocytomas and paragangliomas (PPGLs). The focus is on immunotherapy to enable early diagnosis of primary tumors and halt cancer cell proliferation, aiming to improve patient outcomes
  • In June 2022, Ariceum Therapeutics was launched with a substantial EUR 25 million funding aimed at enhancing the diagnosis and systemic targeted radiation therapy for low- and high-grade neuroendocrine cancers. This investment signifies a significant step forward in advancing treatment options for patients suffering from these challenging forms of cancer
  • In March 2022, Ipsen made a significant investment in a cutting-edge electronic autoinjector for Somatuline Autogel/Somatuline Depot (lanreotide), aiming to enhance administration and injection experience for patients with gastroenteropancreatic neuroendocrine tumors, carcinoid syndrome, or acromegaly. This innovative device represents Ipsen's commitment to advancing treatment delivery and improving the overall patient experience in managing these conditions
  • In August 2020, F. Hoffmann-La Roche Ltd obtained priority marketing approval from the European Commission for Rozlytrek. The drug is designated for treating advanced non-small cell lung cancer in both adults and children aged 12 years and above. This regulatory milestone signifies a significant advancement in addressing this challenging medical condition across different age groups

Global Neuroendocrine Tumors Market Scope

The global neuroendocrine tumors market is segmented on the basis of classification, site, grade, type, product, route of administration, end user, and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Classification

  • Functional Net
  • Non-Functional Net

Site

  • Lung
  • Pancreas
  • Gastrointestinal Tract (GI)
  • Appendicular

 Grade

  • Grade 1
  • Low-Grade Tumor
  • Grade 2
  • Intermediate-Grade Tumor
  • Grade 3
  • High-Grade Tumor

Type

  • Diagnosis
  • Treatment

Product

  • Somatostatin Analogs
  • Targeted Therapy
  • Tyrosine Kinase Inhibitors
  • mTOR Inhibitors
  • Chemotherapy
  • Antimetabolites
  • Alkylating Agents
  • Natural Products

 Route of Administration

  • Oral
  • Parenteral

 End User

  • Hospitals
  • Specialty Clinics
  • Radiation Centers
  • Home Healthcare
  • Others

Distribution Channel

  • Direct Tender
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Other

Global Neuroendocrine Tumors Market Regional Analysis/Insights

The global neuroendocrine tumors market is analysed and market size insights and trends are provided by classification, site, grade, type, product, route of administration, end user, and distribution channel as referenced above.

The countries covered in the global neuroendocrine tumors market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America dominates the neuroendocrine tumors market stems from its robust consumer market and high GDP. The U.S., with the world's highest household spending and trade agreements, serves as a prime market for diagnostic products, solidifying the region's leading position.

In Europe, Germany leads the neuroendocrine tumors market due to rising incidence rates, heightened demand for targeted therapies, and growing disposable incomes. These factors position Germany as a key player in addressing the growing challenges posed by neuroendocrine tumors in the region.

In the Asia-Pacific, China dominates the neuroendocrine tumors market is driven by health remuneration policies covering expenses for such treatments and privileges for senior citizens. These factors contribute to China's prominence in addressing neuroendocrine tumors within the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed base and New Technology Penetration

The global neuroendocrine tumors market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for global neuroendocrine tumors market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the global neuroendocrine tumors market. The data is available for historic period 2016-2021.

Competitive Landscape and Global Neuroendocrine Tumors Market Share Analysis

The global neuroendocrine tumors market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global neuroendocrine tumors market.

Some of the major players operating in the global neuroendocrine tumors market are:

  • F. Hoffmann-La Roche Ltd (Switzerland)
  • Bristol Myers Squibb (U.S.)
  • Viatris Inc. (U.S.)
  • Thermo Fisher Scientific Inc. (U.S.)
  • Novartis AG (Switzerland)
  • Regeneron Pharmaceuticals, Inc. (U.S.)
  • Sun Pharmaceutical Industries Ltd. (India)
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • Eli Lilly and Company (U.S.)
  • Lupin (India)
  • Exact Sciences Corporation (U.S.)
  • Pfizer Inc. (U.S.)
  • Ipsen Pharma (France)
  • Advanced Accelerator Applications (France)
  • BioSynthema Inc. (U.S.)
  • Bionano Genomics, Inc.U.S.)
  • Illumina, Inc. (U.S.)
  • GSK plc (U.K.)
  • HUTCHMED (China)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

FREQUENTLY ASK QUESTIONS

The Neuroendocrine Tumors Market size will be worth USD 7,132.24 million by 2031 during the forecast period.
The Neuroendocrine Tumors Market growth rate is 10.4% during the forecast period.
The Growing Awareness among Healthcare Professionals and Rising Incidence of Neuroendocrine Tumors Globally are the growth drivers of the Neuroendocrine Tumors Market.
The classification, site, grade, type, product, route of administration, end-user, and distribution channel are the factors on which the Neuroendocrine Tumors Market research is based.
The major companies in the Neuroendocrine Tumors Market are F. Hoffmann-La Roche Ltd (Switzerland), Bristol Myers Squibb (U.S.), Viatris Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Novartis AG (Switzerland), Regeneron Pharmaceuticals, Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), Lupin (India), Exact Sciences Corporation (U.S.), Pfizer Inc. (U.S.), Ipsen Pharma (France), Advanced Accelerator Applications (France), BioSynthema Inc. (U.S.), Bionano Genomics, Inc.U.S.), Illumina, Inc. (U.S.), GSK plc (U.K.), HUTCHMED (China).
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials